Sandoz Group (OTCMKTS:SDZNY) and Vivos Therapeutics (NASDAQ:VVOS) Head to Head Survey

Sandoz Group (OTCMKTS:SDZNY) and Vivos Therapeutics (NASDAQ:VVOS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Sandoz Group and Vivos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sandoz Group	N/A	N/A	N/A
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%

Earnings & Valuation

This table compares Sandoz Group and Vivos Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sandoz Group	$11.09 billion	3.26	$914.00 million	N/A	N/A
Vivos Therapeutics	$19.57 million	0.43	-$21.17 million	($2.14)	-0.29

Sandoz Group has higher revenue and earnings than Vivos Therapeutics.

Institutional & Insider Ownership

0.1% of Sandoz Group shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Sandoz Group and Vivos Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sandoz Group	0	1	0	3	3.50
Vivos Therapeutics	1	1	2	0	2.25

Vivos Therapeutics has a consensus target price of $2.75, suggesting a potential upside of 350.82%. Given Vivos Therapeutics’ higher possible upside, analysts plainly believe Vivos Therapeutics is more favorable than Sandoz Group.

Risk & Volatility

Sandoz Group has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 6.25, meaning that its stock price is 525% more volatile than the S&P 500.

Summary

Sandoz Group beats Vivos Therapeutics on 8 of the 13 factors compared between the two stocks.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.